• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home The Classics General Medicine Classics

The EPHESUS trial: Eplerenone in heart failure after myocardial infarction [Classics Series]

byAndrew Cheung, MD MBA
April 2, 2014
in General Medicine Classics, The Classics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

Image: PD

1. Eplerenone significantly reduces all-cause mortality in patients with heart failure and left ventricular dysfunction (LVEF≤40%) after myocardial infarction when compared with placebo

2. Eplerenone treatment in this setting also significantly reduced mortality from cardiovascular causes and hospitalizations for cardiovascular issues

Original Date of Publication: April 3, 2003

Study Rundown: At the time of the EPHESUS trial, it had been demonstrated that aldosterone blockade reduces mortality in severe systolic heart failure (as demonstrated in the RALES trial) and prevents ventricular remodeling in patients after an acute myocardial infarction (MI). It was hypothesized that starting a mineralocorticoid antagonist after an acute MI would be beneficial, and the EPHESUS trial was designed to test this proposition. In summary, the trial demonstrated that treatment with eplerenone 3-14 days after an acute MI significantly reduced mortality (RR 0.85; 95%CI 0.75-0.96) and the rate of hospitalization for heart failure (RR 0.85; 95%CI 0.74-0.99).

It has been noted that EPHESUS started randomization several months after data from the RALES trial was published, and one criticism that has been leveled at the EPHESUS trial was regarding their choice of mineralocorticoid antagonist. While the rates of gynecomastia have been lower with eplerenone as compared with spironolactone, the costs of treatment with eplerenone are considerably higher. Moreover, the RALES trial had demonstrated a much larger relative risk reduction in all-cause mortality with spironolactone, thus, some have suggested that EPHESUS should have been conducted with spironolactone instead.

Click to read the study in NEJM

RELATED REPORTS

Dapagliflozin efficacious and safe in treating heart failure

Improved mortality rates for myocardial infarction, stroke, and pulmonary embolism in patients receiving dialysis between 1998 to 2015

Ophthalmologic procedures are not associated with increased risk for acute myocardial infarction

In-Depth [randomized, controlled study]: This multicentre, randomized, controlled study was conducted at 674 centres in 37 countries. In all, 6,642 patients were recruited and randomized to be treated with either eplerenone or placebo in addition to optimal management 3-14 days after suffering an acute MI. Other inclusion criteria were left ventricular ejection fraction (LVEF) ≤40% and clinical findings of heart failure (i.e., pulmonary rales, pulmonary congestion on x-ray, third heart sound). Patients with diabetes did not need clinical evidence of heart failure in order to be included, because of their increased risk of cardiovascular events. Patients were excluded if they were using potassium-sparing diuretics, had serum creatinine >220 µmol/L, or had serum potassium >5.0 mmol/L. There were two primary endpoints: 1) time to death from any cause, and 2) time to death from cardiovascular causes or first hospitalization for a cardiovascular event.

The incidence of both primary endpoints – death from any cause (RR 0.85; 95%CI 0.75-0.96) and death from/hospitalization for cardiovascular causes (RR 0.87; 95%CI 0.79-0.95) – were significantly lower in the eplerenone group as compared to the placebo group. Interestingly, patients in the eplerenone group also had a significantly lower rate of sudden cardiac death (RR 0.79; 95%CI 0.64-0.97) and significantly fewer hospitalizations for heart failure (RR 0.85; 95%CI 0.74-0.99). Not surprisingly, there were significantly more episodes of serious hyperkalemia noted in the eplerenone group compared to the placebo group (5.5% vs. 3.9%, P=0.002). Patients on eplerenone also had significantly more gastrointestinal issues (19.9% vs. 17.7%, P=0.02).

© 2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.

Tags: Eplerenoneheart failuremyocardial infarction
Previous Post

ACE inhibitors associated with decreased mortality in diabetics

Next Post

Lifestyle intervention delays diabetes and reduces mortality

RelatedReports

Radiation dose associated with increased heart disease in Hodgkin lymphoma survivors
Cardiology

Dapagliflozin efficacious and safe in treating heart failure

May 13, 2022
Fish oil and aspirin did not reduce arteriovenous fistula failure: The FAVOURED trail
Cardiology

Improved mortality rates for myocardial infarction, stroke, and pulmonary embolism in patients receiving dialysis between 1998 to 2015

April 22, 2022
Nonpowder gun-related pediatric eye injuries on the rise
Cardiology

Ophthalmologic procedures are not associated with increased risk for acute myocardial infarction

April 22, 2022
30-Day mortality decreased in UK pediatric cardiac surgery from 2000-2010
Cardiology

Interatrial shunt device not effective in patients with symptomatic heart failure

March 29, 2022
Next Post
Added sugar intake associated with mortality from cardiovascular disease

Lifestyle intervention delays diabetes and reduces mortality

Repeat third trimester syphilis screening may not be cost effective

Cerebrovascular procedure complications linked with race/ethnic and socioeconomic factors

New genetic link in pulmonary arterial hypertension holds therapeutic promise

Restrictive red blood cell transfusion may decrease risk of infection

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • 2 Minute Medicine Rewind May 22nd, 2022
  • #VisualAbstract: Severe actinic keratosis and need for additional treatment are markers for an increased risk of cutaneous squamous cell carcinoma
  • Virtual yoga and meditation intervention may be associated with increased health-related quality of life
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.